ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,214.08
0.51%
Dow Jones
39,387.76
0.85%
US Dollar vs MXN
16.75043
-0.26%
Brent Oil
84.175
0.27%
Bitcoin
62,954.68
-0.15%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Alnylam Pharmaceuticals Inc (ALNY)

  7. Alnylam Pharmaceuticals Inc (ALNY) Noticias

ALNY

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ALNY
FechaHoraFuenteTítuloSímboloCompañía
07/05/202407:00Business WireAlnylam Issues 2023 Corporate Responsibility ReportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
02/05/202407:00Business WireAlnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/04/202406:00PR Newswire (Canada)Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including AustraliaNASDAQ:ALNYAlnylam Pharmaceuticals Inc
18/04/202407:00Business WireAlnylam to Webcast Conference Call Discussing First Quarter 2024 Financial ResultsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
07/04/202407:00Business WireAlnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled HypertensionNASDAQ:ALNYAlnylam Pharmaceuticals Inc
20/03/202407:00Business WireAlnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific SessionNASDAQ:ALNYAlnylam Pharmaceuticals Inc
13/03/202406:30Business WireAlnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive DiseaseNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/03/202405:50Business WireAlnylam meldet positive KARDIA-2 Topline-Studienergebnisse, die eine klinisch signifikante Blutdrucksenkung bei Zugabe von Zilebesiran zu Standard-Blutdrucksenkern belegenNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202416:39Business WireAlnylam annonce des résultats positifs de l’étude KARDIA-2 démontrant des réductions cliniquement significatives de la pression artérielle lorsque le zilebesiran est ajouté à des antihypertenseurs standardsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202415:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202406:30Business WireAlnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care AntihypertensivesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
04/03/202415:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
29/02/202415:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
27/02/202407:30Business WireAlnylam to Webcast Presentations at Upcoming March Investor ConferencesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
15/02/202415:23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
15/02/202407:00Business WireAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
09/02/202417:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
29/01/202407:00Business WireAlnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
09/01/202407:05Business WireAlnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s AssociationNASDAQ:ALNYAlnylam Pharmaceuticals Inc
07/01/202417:00Business WireAlnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional UpdatesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
02/01/202406:30Business WireAlnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ALNYAlnylam Pharmaceuticals Inc
13/12/202306:30Business WireAlnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D DayNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/12/202307:00Business WireAlnylam to Webcast Virtual R&D DayNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/11/202307:00Business WireAlnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023NASDAQ:ALNYAlnylam Pharmaceuticals Inc
12/11/202311:08Business WireAlnylam präsentiert positive Ergebnisse der Phase-2-Dosisfindungsstudie KARDIA-1 zu Zilebesiran, einem RNAi-Prüftherapeutikum zur Behandlung von Bluthochdruck bei Patienten mit hohem kardiovaskulärem RisikoNASDAQ:ALNYAlnylam Pharmaceuticals Inc
12/11/202311:08Business WireAlnylam présente des résultats positifs de l'étude KARDIA-1 de Phase 2 de détermination de la dose évaluant zilebesiran, un traitement iARN expérimental en développement pour le traitement de l'hypertension chez les patients à risque...NASDAQ:ALNYAlnylam Pharmaceuticals Inc
11/11/202315:00Business WireAlnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular RiskNASDAQ:ALNYAlnylam Pharmaceuticals Inc
07/11/202307:00Business WireAlnylam to Webcast Presentations at Upcoming November Investor ConferencesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
02/11/202307:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
02/11/202307:00Business WireAlnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ALNY

Su Consulta Reciente

NYSE
JPM
JP Morgan Chase
COIN
ETHUSD
Ethereum
CCOM
US30
US 30
NASDAQ
NVDA
NVIDIA
PM
XAUUSD
Gold vs US Dollar
NYSE
VZ
Verizon Communications
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
KO
Coca Cola
NYSE
XOM
Exxon Mobil
SPI
SP500
S&P 500
USOTC
ADDYY
Adidas (QX)
COIN
BTCUSD
Bitcoin
NYSE
MRK
Merck
NASDAQ
AMZN
Amazon.com
COIN
SOLUSD
Solana
NASDAQ
QQQ
Invesco QQQ Trust Series 1
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados